FibroBiologics, Inc.
FBLG
$0.9364
$0.07648.88%
| Weiss Ratings | FBLG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E- | |||
| Rating Factors | FBLG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | FBLG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | FBLG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -15.64% | |||
| 30-Day Total Return | -18.57% | |||
| 60-Day Total Return | -55.83% | |||
| 90-Day Total Return | -60.66% | |||
| Year to Date Total Return | -52.83% | |||
| 1-Year Total Return | -91.33% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -93.67% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | FBLG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $13.59 | |||
| 52-Week Low Price | $0.86 | |||
| 52-Week Low Price (Date) | Apr 01, 2025 | |||
| 52-Week High Price (Date) | May 29, 2024 | |||
| Valuation | FBLG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 32.45M | |||
| Enterprise Value | 29.02M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.35 | |||
| Earnings Per Share Growth | -48.16% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 11.03 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.94 | |||
| Enterprise Value/EBITDA (TTM) | -2.14 | |||
| Enterprise Value/EBIT | -2.11 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | FBLG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 34.13M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | FBLG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 281 651 5150 | |||
| Address | 455 East Medical Center Boulevard Houston, TX 77598 | |||
| Website | www.fibrobiologics.com | |||
| Country | United States | |||
| Year Founded | 2021 | |||
| Profitability | FBLG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | FBLG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -60.75% | |||
| Return on Equity | -- | |||
| Income Statement | FBLG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -13.58M | |||
| EBIT (TTM) | -13.74M | |||
| Net Income (TTM) | -11.16M | |||
| Net Income Avl. to Common (TTM) | -11.16M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 68.11% | |||
| EPS Diluted (TTM) | -0.35 | |||
| EPS Diluted Growth (Q YOY) | 73.62% | |||
| Balance Sheet | FBLG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 13.99M | |||
| Cash Per Share (Q) | $0.41 | |||
| Total Current Assets (Q) | 14.23M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.74M | |||
| Current Ratio (Q) | 1.118 | |||
| Book Value Per Share (Q) | $0.08 | |||
| Total Assets (Q) | 16.45M | |||
| Total Current Liabilities (Q) | 12.73M | |||
| Total Debt (Q) | 10.55M | |||
| Total Liabilities (Q) | 13.71M | |||
| Total Common Equity (Q) | 2.74M | |||
| Cash Flow | FBLG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -184.00K | |||
| Cash from Financing (TTM) | 16.91M | |||
| Net Change in Cash (TTM) | 4.82M | |||
| Levered Free Cash Flow (TTM) | -11.84M | |||
| Cash from Operations (TTM) | -11.90M | |||
